Pharmaceutical company AbbVie Inc. (ABBV), Thursday announced that its subcutaneous infusion Vyalev will be now available for patients with advanced Parkinson's disease in Canada.
Advanced Parkinson's disease or aPD is a progressive and chronic movement disorder accompanied by the loss of dopamine-producing cells in the brain.
The company stated that Vyalev, a non-surgical treatment option, is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of aPD.
During the clinical trial, patients consuming Vyalev experienced a reduction in motor fluctuations and morning akinesia, along with improvements in sleep quality and quality of life.
In the pre-market activity, AbbVie's stock is trading at $174.99, down 0.01 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.